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Folic acid (FA) has traditionally been associated with prevention of neural tube defects; more recent work
suggests that it may also be involved in in the prevention of adult onset diseases. As the role of FA in human
health and disease expands, it also becomes more critical to understand the mechanisms behind FA action.
In this work we examined the hypothesis that folate receptor alpha (FRa) acts as a transcription factor. FRa
is a GPI-anchored protein and a component of the caveolae fraction. The work described here shows that
FRa translocates to the nucleus, where it binds to cis-regulatory elements at promoter regions of Fgfr4 and
Hes1, and regulates their expression. The FRa recognition domain mapped to AT rich regions on the
promoters. Until this time FRa has only been considered as a folate transporter, these studies describe a
novel role for FRa as a transcription factor.
T
raditionally folic acid (FA)1 has been associated with prevention of neural tube defects; however more
recently FA has been associated with the prevention of adult onset disease, such as Alzheimer’s disease,
dementia, neuropsychiatric disorders, cardiovascular diseases, and cerebral ischemia (reviewed in ref. 2).
Cellular uptake of folate is mediated by specific carriers or receptors, including FRa (folate receptor alpha; also
known as Folr1 and Folbp1)3, proton-coupled folic acid transporter (PCFT), and reduced folic acid carrier (RFC)
(see ref. 4 for review). FRa, a GPI-anchored protein5 is critical for embryonic development6. Disruption of both
FRa alleles in mice results in pups with a range of malformations and is lethal to the embryos at the time of neural
tube closure6. FRa is one of the components of the caveolae fraction7, which includes EGFR8, caveolin-1 (Cav-1)9,
the b subunit of heterotrimeric GTP binding protein (Gb) and protein kinase C a subunit (PKCa)2. Cav-19 and
EGFR10 act as transcription factors by binding to cis-regulatory elements of downstream target genes. EGFR binds
to the promoters of cyclin D1, iNOS, B-Myb,Aurora-A, thymidylate synthase,COX-2, c-Myc, and BCRPwhich are
involved in tumorogenesis, chromosome instability, and chemo-resistance11. Cav-1 binds to the promoters of
cyclin D1 and FRa9, IGF-1 receptor12, BRCA113. This study examines a possible role of another caveolar protein,
FRa as a transcription factor for key developmental genes.
Previous data from our lab2,14,15 demonstrated that FA remodels chromatin structures15. A second mechanism
of FA action may be through FRa translocating to the nucleus and acting as a transcription factor. Bozard and
colleagues16 reported the presence of FRa on the plasma membrane, the nuclear membrane and within endoso-
mal structures; however the relevance of nuclear FRa was not determined. In this work we tested the hypothesis
that in response to FA, FRa translocates to the nucleus and acts as a transcription factor.
To test the role of FRa as a transcription factor we examined nuclear localization in cell lines and interaction of
FRa with two candidate genes FGFR4 and Hes1. These candidate genes were chosen because in our previous
studies, working with neural stem cells from Pax3 mutant (also known as or Splotch (Sp2/2)) mouse embryos, we
found that FA up-regulates Fgfr4 and Fgfr4 receptor protein2 and increases levels of Hes114.
Results
Nuclear localization of FRa. To test the hypothesis that FRa translocates to the nucleus, a time course (0 min,
15 min and 30 min) for FRa nuclear localization was performed in DAOY cells treated with FA. The results of
FRa immunoblots using mouse monoclonal antibody on nuclear extracts (Fig. 1a, b) showed that FRa
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translocates to the nucleus within 15 min of FA incubation. It is to be
noted that a very faint band of immunoreactivity for FRa (38 kd
band) was present in the nucleus even in the absence of FA.
To study FRa distribution in the absence and presence of FA
(30 min), we isolated different subcellular fractions of DAOY cells-
membrane, cytosol, cytoskeletal, nuclear and chromatin enriched
fractions and performed western immunoblots (Fig. 1c) using FRa
antibody along with antibodies against subcellular markers NCAM,
N-cadherin and I-CAM1 (for membrane enriched fraction), hsp90
(for cytosolic enriched fraction), vimentin (for cytoskeletal enriched
fraction), pRB (for nuclear enriched fraction) and histone H3 (for
chromatin bound fraction). The ratio of the average band intensities
of the two immunoreactive bands of FRa (42 kd and 38 kd doublet)
with the marker of individual subcellular fraction (FRa/ICAM-1,
FRa/hsp90, FRa/vimentin, FRa/pRB, and FRa/H3 bands) were
determined using densitometry (Fig. 1d). It is to be noted that all
the membrane markers used here also showed strong immunoreacti-
vity in the nuclear enriched fraction. The hsp90 immunoreactivity
was highest in the cytosolic enriched fractions (C) and the vimentin
antibody cross-reacted with the insoluble cytoskeletal pellet (P). The
pRB immunoreactivity was highest in the nuclear enriched fractions
(N) and histone H3 antibody immunoreacted with the chromatin
bound fraction (CB). In the absence of FA, FRa was predominantly
present in the cytosolic fraction whereas in the presence of FA, the
FRa (42 kd band) appeared to translocate to the non-nuclear frac-
tion (membrane, and cytoskeletal pellet fraction) and the 38 kd band
to the nucleus. In the nucleus the FRa (38 kd band) appeared to be
present in the chromatin bound fraction in the presence of FA.
When the data in Fig. 1e is presented as total non-nuclear fraction
(membrane 1 cytosol 1 insoluble cytoskeletal pellet) and nuclear
fraction (nuclear 1 chromatin bound) we observe that even in the
absence of FA, FRa is present in the nucleus and in the presence of
FA, there is a significant increase in the translocation of FRa to the
nuclear fraction.
Presence of FRa in the nucleus was further confirmed by con-
focal microscopy in DAOY cells (Fig. 1f). pRB was chosen as a
nuclear marker. Increased co-localization of FRa and pRB was
observed in the presence of FA. These results suggest the follow-
ing: (i) In the absence of FA, there is a more FRa in the cytosolic
fraction; (ii) Upon FA treatment, FRa is distributed significantly
to the non-nuclear membrane fraction as well to the nuclear
enriched and chromatin bound fractions; (iii) Of the two immu-
nostained FRa- 42 kd and 38 kd bands, the 42 kd band seems to
translocate to the membrane enriched fraction in the presence of
FA. Although both 42 kd and 38 kd bands of FRa appear to
translocate to the nucleus, only the 38 kd band translocates
Figure 1 | Nuclear localization of FRa. (a) Nuclear extracts fromDAOY cells treated with FA (200 mg/ml) for zero, 15 and 30 min at 37uCwere subjected
to immunoblotting using monoclonal anti-FRa (recognizing a 38 kd band) and polyclonal anti-pRB (recognizing 110 kd band) (see Supplementary Fig
S1). (b) Ratio of FRa/pRB average band intensity (densitometry data is an average1 SEMof three experiments). (c) Subcellular factions fromDAOY cells
not-treated or treated with FA (200 mg/ml) for 30 min were immunoblotted with NCAM, N-cadherin, ICAM-1 vimentin, hsp90, pRB, H3 and FRa
(rabbit polyclonal) antibodies. The FRa polyclonal antibody is made against an epitope corresponding to amino acids 1-257 representing full length FR a
of human origin. This antibody is reported to recognizemultiple types of FR, a, b and perhaps c. Rabbit IgGwas used as a negative control. M,membrane
enriched; C, cytosolic enriched; P, insoluble cytoskeletal enriched; N, nuclear enriched; CB, chromatin bound fraction. The data above is a representative
example of 5 different western blots. (d) The data is the average of 5 different western blot experiments1/2 standard error mean. The ratio of average
band intensity of FRa (42 kd and 38 kd) to subcellular fraction markers: FRa/ICAM-1; FRa/hsp90; FRa/vimentin; FRa/pRB; FRa/H3 was determined
using densitometry. Statistical significance was calculated using Student’s t test. (e) The data in ‘‘d’’ is presented as total non-nuclear fraction comprising
of membrane, cytosol and insoluble cytoskeletal pellet, and total nuclear fraction comprised of nuclear and chromatin bound fractions. Statistical
significance was calculated using Student’s t test. (f) DAOY cells were grown in 8 well chamber slides in DMEMwith 10% FBS for 24 h, then switched to
serum free media in the absence or presence of FA (200 mg/ml) for 30 min at 37uC and immunostained using FRamonoclonal antibody and polyclonal
pRB antibody and subjected to confocal microscopy. Secondary antibodies were donkey anti-rabbit Cy3 (red) and donkey anti-mouse Alexa488 (green).
Yellow signals indicate co-localization of FRa (red) and pRB (green) in the nucleus (also stained blue with DAPI). The data is a representative of five
separate experiments.
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significantly to the chromatin bound fraction in the FA treated
cells.
FRa binds to cis-regulatory elements of gene promoters. The
above studies suggested that FRa translocates to the nucleus and in
the presence of FA, it is enriched in the chromatin bound fraction. To
determine whether FRa activates FGFR4, FGFR4 promoter-luci-
ferase constructs P-535/199 from human FGFR4 promoter17 were
transiently transfected into DAOY cells, treated or not treated with
FA. FGFR4 promoter-luciferase reporter activity increased (p,0.05)
in the presence of FA (Fig. 2a). FRa significantly increased FGFR4
promoter-luciferase in the absence of FA (p,0.001), with a further
increase in the presence of FA (p,0.0001). This demonstrates that
FRa activates FGFR4 promoter by binding to cis-regulatory elements.
To establish if FRa activates other FAmodulated genes by binding
to cis-regulatory regions, mouse Hes1 promoter-luciferase con-
struct18 was co-transfected with FRa expression vector into DAOY
cells treated or not treated with FA.Hes1 is a Pax3 downstream target
gene18, FA increases Hes1 mRNA and protein levels14. Hes1-pro-
moter-luciferase reporter activity increased (p,0.05) in response
to FA. FRa significantly increased (p,0.001) Hes1-promoter-luci-
ferase without FA (Fig. 2b), with a further increase with FA treat-
ment. These data indicate that FRa transcriptional activation is not
limited to FGFR4.
To confirm FRa binding to cis-regulatory elements of Hes1 and
Fgfr4 promoters in intact embryos, chromatin immunoprecipitation
(ChIP) experiments were performed using the lower lumbar region
of the neural tube from wild-type (WT) mouse embryos (E10.0, 30
somite stage), an area where both of these genes are expressed. FRa
bound to cis-regulatory regions of Hes1 and Fgfr4 promoters in vivo
(Fig. 3a).
FRa binds to AANTT consensus sequence on Hes1 or FGFR4
promoter. To identify putative FRa binding sequences in Hes1
and Fgfr4 promoters, 32P-labeled oligonucleotides were made from
appropriate promoter regions and EMSA was performed using
affinity-purified GST-FRa fusion protein (Fig. 3b, c). GST-FRa
fusion protein bound the Hes1 oligonucleotide 59-AAAATTAT-
TTTTTTTTTGCGTGAAG-39 which had AANTT or NAAAAN
and/or NTTTTN sequences. When this sequence was mutated as
in 59-AACCCTTATTCCCCTTTGCGTGAAG-39 there was no
shift. Similarly, on the Fgfr4 promoter the GST-FRa binding site
mapped to AANTT or NAAAAN and/or NTTTTN in the
oligonucleotide 59-CAAACAAACAAAAAGAAACAACAAAAA-
AACTTTTTA-39 and NTTTTTN in the oligonucleotide 59-ATA-
AAAGCACAACTTTTTACAAAGTTTAAAGTTTTTT-39. When
the oligonucleotide sequence did not have the AANTT or TTNAA
and NAAAAN consensus GST-FRa did not show a shift as in the
case of 59-CGTTCGCGTGCAGTCCGAGATAT-39.
To further confirm the identity of FRa binding sites on Hes1 and
FGFR4 promoters, AANTT sites were mutated on Hes1 and FGFR4
promoter-luciferase reporter constructs P-535/199. Mutated con-
structs were transfected into DAOY cells as above. Luciferase activity
did not increase with these constructs for either Hes1 or FGFR4
promoters (Fig. 4a). The results confirm that FRa binds Hes1 and
FGFR4 promoters at AANTT or TTNAA and NTTTTN or
NAAAAN sites.
Discussion
Previous work from our lab demonstrated that in the absence of
functional Pax3, FA increased KDM6B, through up-regulation of
KDM6B targeting micro-RNAs. This in turn altered H3K27 methy-
lationmarks on the promoters of Pax3 downstream targets,Hes1 and
Neurog2, and affected gene transcription14. Thus one mechanism of
FA action is through remodeling of chromatin structures. In this
studywe have elucidated a secondmechanism for FA action, through
activation of FRa and its’ subsequent action as a transcription factor.
A hypothetical model showing FRa internalization is presented in
Fig. 4b. FRa is internalized in a caveolar structure as early endo-
some19. The endosome becomes increasingly acidic20 and fuses with
a lysosome21. In the lysosome FA is released22 and lysosomal GPI-
specific phospholipase D23 cleaves off the GPI anchor on FRa, which
is then set free. Free FRa translocates into the nucleus where it binds
to cis-regulatory elements of target genes and directly activates tran-
scription. This model does not take into account FRa recycling and it
is still unclear exactly how FRa translocates into the nucleus.
Binding toHes1 and Fgfr4 promoters suggests FRa involvement in
stem cell maintenance and skeletal muscle differentiation, respect-
ively. The list of putative FRa targets shown in Table 1, suggests that
FRamay be involved in regulating a plethora of developmental genes
involved in myogenesis, skeletonogenesis, cell mobility, neural crest
cell migration, cranial and cardiac neural crest formation, hair mor-
phogenesis, oligodendrogenesis, spermatogenesis24, melanogen-
esis25, and epithelial to mesenchymal transformation26. A survey of
the promoter regions of c-Met, PDGFa, TGFb2, MITF, N-CAM, c-
RET,MyoDandTyrp-1 indicates that the FRa bindingmotif AANTT
Figure 2 | Activation of Pax3 downstream target genes by FRa. FRa-pcDNA3 or control pcDNA3 (0.2 ng/well) constructs were co-transfected withHes1
promoter-luciferase construct (a), human FGFR4 promoter-luciferase construct P-535/19919 (b) or a control PGL3 (promoter-less luciferase gene) into
DAOY cells. FA (200 mg/ml) was added 24 h post transfection. Luciferase activity was assayed 48 h post-transfection. pRLnull (5 ng/well) was used as a
transfection control in all wells. For both Hes1 promoter luciferase and FGFR4 promoter-luciferase construct P-535/199 FRa significantly increased
promoter activity, with the highest increases observed in the presence of FA. Experiments were performed in quadruplicate with each data point in
duplicate. * p,0.05; ** p,0.001; *** p,0.0001 (Student T-test).
www.nature.com/scientificreports
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Figure 3 | FRa binds to murine Hes1 and Fgfr4 promoter cis-regulatory elements. (a) ChIP assays was performed using E10.0 (30 somite) lumbar
neural tube. Anti-FRa polyclonal antibody was used to immunoprecipitate (IP) the protein–DNA complex. This antibody is made against epitope
corresponding to amino acids 1-257 representing full length FR a of human origin. This antibody is reported to recognize multiple types of FR, a, b and
perhaps c. Primers used to amplify cis-regulatory elements inHes1 and Fgfr4 promoters are shown in Supplementary Information Table 1. Rabbit IgGwas
used as an IP negative control. ChIP experiments were performed in triplicate using one lumbar neural tube region per assay with a total of n54.
(b) EMSA of binding reactions performed using GST-FRa fusion protein and 32P-labeled double-stranded oligonucleotides. MouseHes1 oligo #1 (with
AANTT): 59-AAAAAATTATTTTTTTTTTGCGTGAAG-39; Mouse Hes1 oligo #2 (mutant AAA.CCC): 59-AAACCCTATTTCCCCTTTGCGTGAAG-
39: (c)Mouse Fgfr4 oligo #3 (with AANTT): 59-CAAACAAACAAAAAGAAACAACAAAAAAACTTTTTA-39; Mouse Fgfr4 oligo #4 (with AANTT): 59-
ATAAAAGCACAACTTTTTACAAAGTTTAAAGTTTTTT-3; Mouse Fgfr4 oligo #5 (deletion mutant without AANTT) 59-
CGTTCGCGTGCAGTCCGAGATAT-39. The arrow shows GST-FRa binding to oligonucleotides which have the AANTT sequence.
Figure 4 | FA does not activate Hes1 or FGFR4 promoter luciferase activity when the FRa consensus sequence (AANTT) is mutated. (a) AA.CC
substitution mutations were made at the putative FRa binding sites on Hes1 or FGFR4 promoters (mutated sites are shown in the supplemental
information).Hes1 promoter-luciferase containing plasmid or plasmids containingmutated sequences (20 ng) were transiently co-transfected with FRa-
pcDNA3 or pcDNA3 vector control into DAOY cells treated or not treated with FA and luciferase assays were performed. Renilla luciferase plasmid,
pRLnull (5 ng/well) was simultaneously transfected as an insertional control for transfection efficiency. FRa-pcDNA3 values were expressed as the activity
of Firefly-luciferase, minus values obtained for control pcDNA3 transfection. Experiments were performed in triplicate with each data point in duplicate;
*p,0.05; **p,0.001; ***p,0.0001 (Student T-test). (b) A hypothetical working model depicting FRa as a transcription factor. FRa, a GPI-anchored
protein, gets internalized in a caveolar structured early endosomes, which undergo acidification and subsequent fusion with lysosomes. GPI-specific
phospholipase D cleaves FRa from its GPI-anchor. FRa is released and translocates to the nucleus via an unknown mechanism(s) where it binds cis-
regulatory elements of different gene promoters.
www.nature.com/scientificreports
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or NTTTTN and/or NAAAAN map close to Pax3, a transcription
factor and multifunctional regulatory protein, expressed early in
embryogenesis, binding sites, which map to ATTA, GTTCC,
TAAT, CCTTG, CAAGG, GTTAT, TATTG, GTGTGA, and
CAGTGT27. These observations suggest that FRa and Pax3 might
appear as a complex regulating target genes synergistically. However,
up-regulation of Hes1 or Neurog2 in FA-rescued Sp2/2 embryos14
suggests that FRa may also have a role independent of Pax3.
Future work shall test this hypothesis.
The observation that FRa acts like a transcription factor is relevant
to our understanding of the mechanisms of FA action during
development and has significant implications for disorders assoc-
iatedwith FAdeficiency and FRamisregulation and formanagement
of human cancers which express FRa as a tumor antigen. FAhas been
associated with the prevention of adult onset diseases (reviewed in
ref. 2). In some of these cases FA deficiency may not be the problem.
The issue may be an inability to respond to FA due to misregulation
of FRa. Cazzaniga and colleagues28 compared levels of serum folate
and assessed differences in folate binding ability with primary fibro-
blast cultures, from Alzheimer’s disease (AD) patients and age-
matched healthy subject. Circulating folate was significantly lower
in ADpatients, whereas folate binding to fibroblasts was significantly
higher, possibly due to enhanced expression of FRa in AD fibro-
blasts. Cerebral folate transport deficiency is an inherited brain-spe-
cific folate transport defect caused bymutations in the folate receptor
1 (FOLR1) gene which codes for FRa29. This disorder generally has a
late infantile onset and symptoms include progressive movement
disturbance, psychomotor decline, epilepsy and disturbed brain
myelination, as well as a depletion of white matter choline and ino-
sitol30. Grapp and colleagues29 reported that whereas WT FRa was
localized in the plasma membrane, in cerebral folate deficiency FRa
mutants were mistargeted to intracellular compartments. The data
presented in this paper provides relevant insight to these clinical
situations. If FA interaction with FRa is misregulated, key transcrip-
tional events may be affected. This in turn can lead to a series of
developmental consequences or to adult onset disease associated
with FA levels. Further work needs to be done to examine direct
transcriptional activation of FRa responsive genes by FRa and its’
role in these multifactorial diseases.
Another clinical role for FRa is in cancer, where it is recognized as
a tumor antigen/biomarker31. Because of this, diagnostic and thera-
peutic methods which exploit FRa are being developed for cancer
treatment, including the use of folate-drug conjugates31. The know-
ledge that FRa acts as a transcription factor can be exploited to target
FA-siRNA or FA-drug conjugates to silence downstream targets in
appropriate cancers. For instance, two Pax3 downstream targets c-
MET and MITF are associated with melanoma32. MET promotes the
melanoma phenotype by stimulating migration, invasion, resistance
to apoptosis, and tumor cell growth. PAX3 mediates MET induction
through direct activation of the gene, and indirect regulation through
MITF. FA-drug conjugates exploiting the proximity of Pax3 and FRa
binding sites could potentially silence c-met and/orMITF expression.
In summary, our study shows that FRa is localized in the nucleus,
where it binds to cis-regulatory elements (AANTT or TTNAA and
NTTTTN or NAAAAN) on FA modulated genes and activates their
transcription. This novel role of FRa as a transcription factor pro-
vides insight into developmental mechanisms associated with FA
responsiveness. It also provides an exciting new avenue to explore
for treatment of diseases associated with FA deficiency, FRa misre-
gulation and cancers which express FRa as a biomarker.
Methods
Antibodies and reagents. pRb antibody-rabbit polyclonal; 151000, Cell Signaling
Technologies: Ser807/811, FRa antibody-rabbit polyclonal; 15500. Santa Cruz: sc-
28997), NCAM (Santa Cruz; sc-1507), N-Cadherin (Santa Cruz; sc-1502), I-CAM-
1(Santa Cruz; sc-1510), vimentin (BD Pharmingen; 550513); pRB (Cell Signaling
Technologies, Ser807/811 rabbit polyclonal; 151000); Histone H3 (Cell Signaling
Technologies, 9701, rabbit polyclonal 151000); Mouse monoclonal anti-FRa
antibody from Lifespan biosciences (cat # LS-C23683). Donkey anti-rabbit IgG-HRP
(sc-2305), and Donkey anti-mouse IgG-HRP (sc-2306) were from Santa Cruz. DAPI
was purchased from Sigma. Secondary antibodies for immunostaining procedures
were donkey anti-rabbit Cy3 (red) (15200) and donkey anti-mouse Alexa488 (green)
(15200).Primers and oligonucleotides for EMSA were from Operon.Wild type (WT)
C57BL/6J male and female mice were from Jackson Labs. For timed embryos, females
and males were mated, the morning a vaginal plug was observed was noted as E0.5.
Pregnant dams were euthanized by cervical dislocation with CO2 inhalation, and
moniliform uterine beads were removed at E10.5. Neural tubes were dissected out as
described earlier33. All animal experiments were approved by IACUC -Children’s
Hospital of Chicago Research Center, Chicago (Approval # Mayanil, IACUC ID: 13-
001.0 09) and all experiments were performed in accordance with relevant
institutional guidelines and regulations.
Statistical analysis. Values given are means: SEM. Probabilities (p) were calculated
with Student’s unpaired t test usingGraphPad Prism version 4.0. p values, 0.05 were
considered statistically significant. One-way ANOVA with Bonferroni’s multiple
comparison tests were used for multiple comparisons between data.
Nuclear localization of FRa.DAOY cells were treated with FA (200 mg/ml) for zero,
15 and 30 minutes at 37uC. For the western blots studies, the DAOY cells not-treated
or treated with FA for 30 min were used. Subcellular fractions, membrane enriched,
cytosolic, insoluble pellet cytoskeletal fraction, nuclear and chromatin bound
fractions (30 mg) were immunoblotted with antibodies against FRa (rabbit
polyclonal, 15500), NCAM (15500); N-Cadherin (151000); I-CAM-1 (151000);
vimentin (1510,000); pRB (15500) and Histone H3 (15500). This rabbit polyclonal
anti-FRa antibody is made against epitope corresponding to amino acids 1-257
representing full length FR a of human origin. This antibody is reported to recognize
multiple types of FR, a, b and perhaps c. The average band intensity of FRa/ICAM-1;
FRa/hsp90; FRa/vimentin; FRa/pRB; FRa/H3 was determined using densitometry.
For immunostaining, DAOY cells were plated and grown inDMEMwith 10%FBS for
24 hours and then changed to serum-free media. FA (200 mg/ml) was added to
appropriate wells. The cells were allowed to grow for an additional 30 min. Cells were
immunostainedwith anti-FRa (mousemonoclonal antibody; 15100) and pRB (rabbit
polyclonal; 15100). This mouse monoclonal FRa antibody recognizes only the 38 kd
band of FRa. Rabbit IgG was used as a negative control. Secondary antibodies were
donkey anti-rabbit Cy3 (red) (15200) and donkey anti-mouse Alexa488 (green)
(15200). Confocal microscopy was done with a Zeiss 510 META Confocal Laser
Scanning Microscope.
Real time quantitative RT-PCR. Real time quantitative RT-PCR was done as
described earlier27. Primers and probes used in this study were designed using Primer
Express software (PerkinElmer Life Sciences). Primers were synthesized by Operon
Inc. probes were synthesized by MegaBases Inc (Refer Supplementary Information-
Table 1 for primers).
Chromatin immunoprecipitation (ChIP) assays. ChIP assays using lumbar neural
tube from WT embryos (E10.0) were performed as described earlier34. PCR was
performedwith primers formurineHes1 and Fgfr4 promoter regions (Supplementary
Information-Table S1 for primers). All ChIP samples were tested for false-positive
PCR amplification by sequencing the 200-bp amplified product to ascertain the
specificity of FRa binding to cis-regulatory elements.
Analysis of Hes1 and Fgfr4 promoter activity. A 2.5 kb Hes1 promoter-luciferase
construct was provided by Dr. R. Kageyama, Institute for Virus Research, Kyoto
University Kyoto, Japan. Human FGFR4 promoter constructs were provided by Dr
Shereen Ezzat, Departments of Medicine, Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, Canada. The FRa expression construct in pcDNA3
was kindly provided by Dr Asok Antony, Indiana University Medical School
Indianapolis, IN, USA. Renilla luciferase plasmid, pRL-null (0.5 mg) (dual luciferase
system, Promega), was simultaneously transfected as an insertional control for
transfection efficiency in all of the studies. DAOY cells were seeded at 53 104 cells/
60 mm diameter dish in DMEM supplemented with 10% fetal calf serum for 24 h
prior to transfection. For co-transfections: human FRa cDNA and mouse Hes1-Luc
promoter or human FRa cDNA and human FGFR4-Luc promoter were transfected
into the cells usingMegaTran 1.0 fromOriGene; Cat#: TT200003. After 24 h, FA was
added to the treatment wells. The cells were washed 3 times with phosphate-buffered
saline (PBS) and lysed with Passive Lysis Buffer (PLB) 48 h post transfection.
Luciferase activity was measured using a Vector 2 Luminometer (PerkinElmer Life
Sciences). The AA.CC substitution mutations of the putative FRa binding sites on
murineHes1 or human FGFR4 promoters were made with the QuickChangeXL site-
directed mutagenesis kit (Stratagene). Hes1 promoter-luciferase containing plasmid
or plasmids containing the mutated sequences (20 ng) were transiently co-
transfected with FRa- pcDNA3 or pcDNA3 vector control into DAOY cells and
luciferase assays were done as described earlier34 using the Dual Luciferase kit from
Promega. Renilla luciferase plasmid, pRL-null (5 ng/well) (Dual Luciferase System
Promega), was simultaneously transfected as an insertional control for transfection
efficiency.
Purification of GST-FRa fusion protein. GST-FRa fusion plasmid was kindly
provided by Dr. Asok Antony. Escherichia coliwas transformed withGST-FRa fusion
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plasmid, and the cells were grown overnight in LB medium. GST-FRa fusion protein
production was induced with 0.1 mM isopropyl-D-thiogalactopyranoside (Sigma)
for 2 hr. Cells were pelleted and sonicated to release the protein in 50 mM Tris-HCl
pH7.8 buffer. Supernatant containing GST-FRa fusion protein among other proteins
was loaded onto glutathione-Sepharose 4B column (Amersham Pharmacia Biotech).
Unbound proteins were washed with 50 mM Tris-HCl pH7.8 buffer and eluted with
10 mM reduced glutathione in 50 mM Tris-HCl, pH 9.5. Eluted protein was
concentrated using Centricon 10 (Amicon) as per the manufacturer’s instruction.
Electro-mobility shift assays (EMSA). Probes were prepared for EMSA by annealing
complementary oligonucleotides representing selected regions of murine Hes1 and
Fgfr4 promoters, followed by 59-end labeling with [c-32P] ATP by T4 polynucleotide
kinase. EMSA was done as described earlier18. Double-stranded oligonucleotide
probes produced, covered the following regions: WT Hes1 promoter oligo: 59-
AAAAAATTATTTTTTTTTTGCGTGAAG-39 andmutantHes1 promoter oligo: 59-
AAACCCTTATTCCCCTTTTGCGTGAAG-39; WT Fgfr4 promoter oligo #1: 59-
CAAACAAACAAAAAGAAACAACAAAAAAACTTTTTA-39WT promoter oligo
#2: 59-ATAAAAGCACAACTTTTTACAAAGTTTAAAGTTTTTT-39 and an oligo
without AANTT sequence #3: 59-CGTTCGCGTGCAGTCCGAGATAT-39. For shift
assays 4 mg GST-FRa fusion protein was pre-incubated at room temperature for
30 minwith 4 Murea and EMSA reaction buffer (100 mMTris-HCl PH7.5, 500 mM
KCl, 6.5% glycerol, 50 mM pyrophosphate, 25 mM DTT in 2.5% Tween 20, 1 mg/ml
salmon sperm DNA) prior to addition of labeled oligonucleotides. For hot reactions
GST-FRa fusion protein and radio-labeled oligonucleotides were added and pre-
incubated for 30 min at room temperature. For cold reactions GST-FRa fusion
protein and unlabeled oligonucleotides were added, and labeled oligonucleotides
were added after 30 min. After pre-incubation, free DNA and DNA protein
complexes were resolved in 6% polyacrylamide gels (these gels were pre-run at
1000 V and 5 mA for 16 h in the continuous cooling system) using 0.253 TBE as the
running buffer. Electrophoresis was performed at 1000 V and 25 mA for 2 h in a
continuous cooling system. To visualize shifted bands, gels were dried at RT and
transferred to Phosphor Imager Screens (Amersham Biosciences). Gels were exposed
overnight at 4uC.
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